Actos Bladder Cancer Lawsuit
Victims continue to file Actos lawsuits against Takeda Pharmaceuticals

Actos (pioglitazone) is a medication used to regulate insulin in patients diagnosed with type II diabetes. It has grown in popularity since its release in July 1999 and has brought in impressive sales of $4.3 billion in 2010 for Takeda Pharmaceuticals. Although Actos has brought much success to Takeda Pharmaceuticals, many consumers have recently brought forth claims against the company alleging that use of Actos causes bladder.

In September of 2010, the Food and Drug Administration (FDA) began reviewing the risks associated with Actos use and posted the safety review on its website. The results found that there is in fact a potential risk of bladder cancer associated with long term use of Actos. In August of 2011, the FDA issued new warning labels stating the bladder cancer risk associated with Actos.

French regulators issued an Actos recall in June 2011 due to a number or bladder cancers cases that were being reported. However, the European Commission advocates Actos as a valid treatment for type II diabetes and has mandated stronger warning labels for the medication along with intense patient screenings.

Millions of lawsuits have been filed against Takeda Pharmaceuticals, claiming that taking the drug causes bladder cancer. Victims of these side effects seek judgement for financial compensation and medical monitoring. The company is alleged of not properly researching the medication and for failing to label the drug with stronger warnings.

Currently, Actos attorneys are in the process of making a decision regarding the location for pretrial litigation. On December 1, 2011 the U.S. Judicial Panel on Multidistrict Litigation met to discuss whether Actos would be centralized before one judge. On December 29, 2011, the panel of judges agreed to centralize all Actos lawsuits before Rebecca F. Doherty in the Western District of Louisiana.


About the Contributor

Related Posts